GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (NAS:GOSS) » Definitions » Debt-to-Equity

Gossamer Bio (Gossamer Bio) Debt-to-Equity : 3.39 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Debt-to-Equity?

Gossamer Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $14.92 Mil. Gossamer Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $197.55 Mil. Gossamer Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $62.77 Mil. Gossamer Bio's debt to equity for the quarter that ended in Dec. 2023 was 3.38.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Gossamer Bio's Debt-to-Equity or its related term are showing as below:

GOSS' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.88   Med: 0.57   Max: 18.69
Current: 3.39

During the past 8 years, the highest Debt-to-Equity Ratio of Gossamer Bio was 18.69. The lowest was -0.88. And the median was 0.57.

GOSS's Debt-to-Equity is ranked worse than
97.1% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs GOSS: 3.39

Gossamer Bio Debt-to-Equity Historical Data

The historical data trend for Gossamer Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Debt-to-Equity Chart

Gossamer Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial 0.11 0.57 1.53 18.69 3.39

Gossamer Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.69 -7.82 -3.49 2.06 3.39

Competitive Comparison of Gossamer Bio's Debt-to-Equity

For the Biotechnology subindustry, Gossamer Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gossamer Bio's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gossamer Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Gossamer Bio's Debt-to-Equity falls into.



Gossamer Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Gossamer Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Gossamer Bio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gossamer Bio  (NAS:GOSS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Gossamer Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Gossamer Bio (Gossamer Bio) Business Description

Traded in Other Exchanges
Address
3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Executives
Sandra Milligan director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Bryan Giraudo officer: Chief Financial Officer 7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Richard Aranda officer: Chief Medical Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Faheem Hasnain director, officer: Executive Chairman 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waage Christian officer: EVP & General Counsel RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Caryn Peterson officer: EVP, Regulatory Affairs 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Laura Carter officer: Chief Scientific Officer 3013 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Luisa Salter-cid officer: Chief Scientific Officer C/O GOSSAMER BIO, INC., 3013 SCIENCE PARK ROAD, SUITE 200, SAN DIEGO CA 92121
Jakob Dupont officer: Chief Medical Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Sheila Gujrathi director, officer: President & CEO 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Russell J. Cox director C/O JAZZ PHARMACEUTICALS, PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2